New injection method aims to make opioid addiction treatment easier to start

NCT ID NCT06441604

Ongoing Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 4 times

Summary

This study tests whether a long-acting buprenorphine injection can be used to start treatment for opioid use disorder without causing severe withdrawal. Thirty adults with opioid use disorder will stay in a hospital for three days, receive fentanyl to prevent withdrawal, and then get one injection of extended-release buprenorphine at different doses. Researchers will monitor safety and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extended-release buprenorphine injection
What this could lead to: If successful, this could offer a safer, more comfortable way to start buprenorphine treatment for opioid use disorder, reducing the risk of severe withdrawal symptoms.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. There is a risk of precipitated withdrawal despite the use of fentanyl.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02118-5605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.